Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations

Author(s): Tannaz Akbari Kolagar, Maryam Farzaneh, Negin Nikkar and Seyed Esmaeil Khoshnam*

Volume 15, Issue 2, 2020

Page: [102 - 110] Pages: 9

DOI: 10.2174/1574888X14666190823142911

Price: $65

Abstract

Neurodegenerative diseases are progressive and uncontrolled gradual loss of motor neurons function or death of neuron cells in the central nervous system (CNS) and the mechanisms underlying their progressive nature remain elusive. There is urgent need to investigate therapeutic strategies and novel treatments for neural regeneration in disorders like Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Currently, the development and identification of pluripotent stem cells enabling the acquisition of a large number of neural cells in order to improve cell recovery after neurodegenerative disorders. Pluripotent stem cells which consist of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are characterized by their ability to indefinitely self-renew and the capacity to differentiate into different types of cells. The first human ESC lines were established from donated human embryos; while, because of a limited supply of donor embryos, human ESCs derivation remains ethically and politically controversial. Hence, hiPSCs-based therapies have been shown as an effective replacement for human ESCs without embryo destruction. Compared to the invasive methods for derivation of human ESCs, human iPSCs has opened possible to reprogram patient-specific cells by defined factors and with minimally invasive procedures. Human pluripotent stem cells are a good source for cell-based research, cell replacement therapies and disease modeling. To date, hundreds of human ESC and human iPSC lines have been generated with the aim of treating various neurodegenerative diseases. In this review, we have highlighted the recent potentials, advances, and limitations of human pluripotent stem cells for the treatment of neurodegenerative disorders.

Keywords: Neurodegenerative diseases, embryonic stem cells, Induced pluripotent stem cells, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis.

Next »
[1]
Gao H-M, Hong J-S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008; 29(8): 357-65.
[http://dx.doi.org/10.1016/j.it.2008.05.002]
[2]
Wu YY, Chiu FL, Yeh CS, Kuo HC. Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease. Royal Society Open Biology 2019; 9(1) 180177
[http://dx.doi.org/10.1098/rsob.180177]
[3]
Santiago JA, Bottero V, Potashkin JA. dissecting the molecular mechanisms of neurodegenerative diseases through network biology. Front Aging Neurosci 2017; 9: 166-6.
[http://dx.doi.org/10.3389/fnagi.2017.00166]
[4]
Latchney SE, Eisch AJ. Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: Regeneration and beyond. Eur J Neurodegener Dis 2012; 1(3): 335-51.
[5]
Chang CY, Ting HC, Liu CA, et al. Induced pluripotent stem cells: A powerful neurodegenerative disease modeling tool for mechanism study and drug discovery. Cell Transplant 2018; 27(11): 1588-602.
[http://dx.doi.org/10.1177/0963689718775406]
[6]
Wang H. Modeling neurological diseases with human brain organoids. Front Synaptic Neurosci 2018; 10: 15.
[http://dx.doi.org/10.3389/fnsyn.2018.00015]
[7]
Simara P, Motl JA, Kaufman DS. Pluripotent stem cells and gene therapy. Transl Res 2013; 161(4): 284-92.
[http://dx.doi.org/10.1016/j.trsl.2013.01.001]
[8]
Vazin T, Freed WJ. Human embryonic stem cells: Derivation, culture, and differentiation: A review. Restor Neurol Neurosci 2010; 28(4): 589-603.
[9]
Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292(5819): 154-6.
[10]
Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 1981; 78(12): 7634-8.
[http://dx.doi.org/10.1073/pnas.78.12.7634]
[11]
Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282(5391): 1145-7.
[12]
Zhu Z, Huangfu D. Human pluripotent stem cells: an emerging model in developmental biology. Development 2013; 140(4): 705-17.
[http://dx.doi.org/10.1242/dev.086165]
[13]
Volarevic V, Markovic BS, Gazdic M, et al. Ethical and safety issues of stem cell-based therapy. Int J Med Sci 2018; 15(1): 36.
[http://dx.doi.org/10.7150/ijms.21666]
[14]
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-72.
[15]
Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-20.
[16]
Yamanaka S. Induced pluripotent stem cells: Past, present, and future. Cell Stem Cell 2012; 10(6): 678-84.
[http://dx.doi.org/10.1016/j.stem.2012.05.005]
[17]
Narsinh KH, Plews J, Wu JC. Comparison of human induced pluripotent and embryonic stem cells: Fraternal or identical twins? Mol Ther 2011; 19(4): 635-8.
[http://dx.doi.org/10.1038/mt.2011.41]
[18]
Omole AE, Fakoya AOJ. Ten years of progress and promise of induced pluripotent stem cells: Historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ 2018; 6e4370
[http://dx.doi.org/10.7717/peerj.4370]
[19]
Khan M. Ethics analysis of the human embryonic stem cell research debate. Online J Health Ethics 2008; 5(2): 4.
[http://dx.doi.org/10.18785/ojhe.0502.04]
[20]
Saha B, Borgohain M, Dey C, Thummer R. iPS cell generation: Current and future challenges. Ann Stem Cell Res Ther 2018; 1(2): 1007.
[21]
Muhammad F. The current state of pluripotency affairs in hiPSCs. J Mol Cloning Genet Recomb 2012.
[22]
Ohnuki M, Takahashi K. Present and future challenges of induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci 1680; 2015: 370.
[23]
Sharkis SJ, Jones RJ, Civin C, Jang YY. Pluripotent stem cell–based cancer therapy: Promise and challenges. Sci Transl Med 2012; 4(127)127ps9
[24]
Lunn JS, Sakowski SA, Hur J, Feldman EL. Stem cell technology for neurodegenerative diseases. Ann Neurol 2011; 70(3): 353-61.
[http://dx.doi.org/10.1002/ana.22487]
[25]
Desai N, Rambhia P, Gishto A. Human embryonic stem cell cultivation: Historical perspective and evolution of xeno-free culture systems. Reprod Biol Endocrinol 2015; 13(1): 9.
[http://dx.doi.org/10.1186/s12958-015-0005-4]
[26]
Tannenbaum SE, Turetsky TT, Singer O, et al. Derivation of xeno-free and GMP-grade human embryonic stem cells–platforms for future clinical applications. PLoS One 2012; 7(6) e35325
[http://dx.doi.org/10.1371/journal.pone.0035325]
[27]
Khan FA, Almohazey D, Alomari M, Almofty SA. Isolation, culture, and functional characterization of human embryonic stem cells: Current trends and challenges. Stem Cells Int 2018; 2018: 9.
[http://dx.doi.org/10.1155/2018/1429351]
[28]
Ezashi T, Telugu BP, Alexenko AP, Sachdev S, Sinha S, Roberts RM. Derivation of induced pluripotent stem cells from pig somatic cells. Proc Natl Acad Sci USA 2009; 106(27): 10993-8.
[http://dx.doi.org/10.1073/pnas.0905284106]
[29]
Farzaneh M, Attari F, Khoshnam SE. Concise review: LIN28/let-7 signaling, a critical double-negative feedback loop during pluripotency, reprogramming, and Tumorigenicity. Cell Reprogram 2017; 19(5): 289-93.
[http://dx.doi.org/10.1089/cell.2017.0015]
[30]
Farzaneh M, Alishahi M, Derakhshan Z, Sarani NH, Attari F, Khoshnam SE. The expression and functional roles of miRNAs in embryonic and lineage-specific stem cells. Curr Stem Cell Res Ther 2019; 14(3): 278-89.
[http://dx.doi.org/10.2174/1574888X14666190123162402]
[31]
Farzaneh M, Derakhshan Z, Hallajzadeh J, Sarani NH, Nejabatdoust A, Khoshnam SE. Suppression of TGF-β and ERK signaling pathways as a new strategy to provide rodent and non-rodent pluripotent stem cells. Curr Stem Cell Res Ther 2019; 14(6): 466-73.
[http://dx.doi.org/10.2174/1871527318666190314110529]
[32]
van der Valk J, Bieback K, Buta C, et al. Fetal bovine serum (FBS): Past–present–future. ALTEX-. Altern Anim Exp 2018; 35(1): 99-118.
[http://dx.doi.org/10.14573/altex.1705101]
[33]
Meng G, Liu S, Li X, Krawetz R, Rancourt DE. Derivation of human embryonic stem cell lines after blastocyst microsurgery. Biochem Cell Biol 2010; 88(3): 479-90.
[http://dx.doi.org/10.1139/O09-188]
[34]
Ström S1, Inzunza J, Grinnemo KH, et al. Mechanical isolation of the inner cell mass is effective in derivation of new human embryonic stem cell lines. Hum Reprod 2007; 22(12): 3051-8.
[http://dx.doi.org/10.1093/humrep/dem335]
[35]
Tanaka N, Takeuchi T, Neri QV, Sills ES, Palermo GD. Laser-assisted blastocyst dissection and subsequent cultivation of embryonic stem cells in a serum/cell free culture system: Applications and preliminary results in a murine model. J Transl Med 2006; 4(1): 20.
[http://dx.doi.org/10.1186/1479-5876-4-20]
[36]
Turetsky T, Aizenman E, Gil Y, et al. Laser-assisted derivation of human embryonic stem cell lines from IVF embryos after preimplantation genetic diagnosis. Hum Reprod 2007; 23(1): 46-53.
[http://dx.doi.org/10.1093/humrep/dem351]
[37]
Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nat Biotechnol 2000; 18(4): 399-404.
[http://dx.doi.org/10.1038/74447]
[38]
Xu C, Rosler E, Jiang J, et al. Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium. Stem Cells 2005; 23(3): 315-23.
[http://dx.doi.org/10.1634/stemcells.2004-0211]
[39]
Bergström R, et al. Xeno-free culture of human pluripotent stem cells Human Pluripotent Stem Cells. Springer 2011; pp. 125-36.
[http://dx.doi.org/10.1007/978-1-61779-201-4_9]
[40]
Amit M, Margulets V, Segev H, et al. Human feeder layers for human embryonic stem cells. Biol Reprod 2003; 68(6): 2150-6.
[http://dx.doi.org/10.1095/biolreprod.102.012583]
[41]
Cheng L, Hammond H, Ye Z, Zhan X, Dravid G. Human adult marrow cells support prolonged expansion of human embryonic stem cells in culture. Stem Cells 2003; 21(2): 131-42.
[http://dx.doi.org/10.1634/stemcells.21-2-131]
[42]
Cho M, Lee EJ, Nam H, et al. Human feeder layer system derived from umbilical cord stromal cells for human embryonic stem cells. Fertil Steril 2010; 93(8): 2525-31.
[http://dx.doi.org/10.1016/j.fertnstert.2010.03.027]
[43]
Aguilar-Gallardo C, Poo M, Gomez E, et al. Derivation, characterization, differentiation, and registration of seven human embryonic stem cell lines (VAL-3,-4,-5,-6M,-7,-8, and-9) on human feeder. In Vitro Cell Dev Biol Anim 2010; 46(3-4): 317-26.
[http://dx.doi.org/10.1007/s11626-010-9285-3]
[44]
Lee JE, Lee DR. Human embryonic stem cells: Derivation, maintenance and cryopreservation. Int J Stem Cells 2011; 4(1): 9-17.
[http://dx.doi.org/10.15283/ijsc.2011.4.1.9]
[45]
Desai N, Rambhia P, Gishto A. Human embryonic stem cell cultivation: Historical perspective and evolution of xeno-free culture systems. Reproductive biology and endocrinology. Reprod Biol Endocrinol 2015; 13: 9.
[46]
Unger C, Skottman H, Blomberg P, Dilber MS, Hovatta O. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Genet 2008; 17(R1): R48-53.
[http://dx.doi.org/10.1093/hmg/ddn079]
[47]
Li W1, Li K, Wei W, Ding s. Chemical approaches to stem cell biology and therapeutics. Cell Stem Cell 2013; 13(3): 270-83.
[http://dx.doi.org/10.1016/j.stem.2013.08.002]
[48]
Baharvand H, Pakzad M. Xeno-free and a feeder free self-renewal extracellular matrix for long-term maintenance of undifferentiated human pluripotent stem cells and method of synthesizing the same Google Patent. 2014.
[49]
Yao S, Chen S, Clark J, et al. Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. Proc Natl Acad Sci USA 2006; 103(18): 6907-12.
[http://dx.doi.org/10.1073/pnas.0602280103]
[50]
Fu X, Toh WS, Liu H, Lu K, Li M, Cao T. Establishment of clinically compliant human embryonic stem cells in an autologous feeder-free system. Tissue Eng Part C Methods 2011; 17(9): 927-37.
[http://dx.doi.org/10.1089/ten.tec.2010.0735]
[51]
Lannon C. A defined, feeder-independent medium for human embryonic stem cell culture. Cell Res 2008; 18(S1): S34.
[http://dx.doi.org/10.1038/cr.2008.124]
[52]
Weber JL, Dolley-Sonneville P, Weber DM. et al. Corning® Synthemax™ Surface: A tool for feeder-free, xeno-free culture of human embryonic stem cells. Nat Methods 2010; 7(12): 1026.
[http://dx.doi.org/10.1038/nmeth.f.316]
[53]
Lambshead JW, Meagher L, O’Brien C, Laslett AL. Defining synthetic surfaces for human pluripotent stem cell culture. Cell Regen (Lond) 2013; 2(1): 7.
[http://dx.doi.org/10.1186/2045-9769-2-7]
[54]
Dantuma E, Merchant S, Sugaya K. Stem cells for the treatment of neurodegenerative diseases. Stem Cell Res Ther 2010; 1(5): 37.
[http://dx.doi.org/10.1186/scrt37]
[55]
Kern RA, Gonzalez R, Garitaonandia I. Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases Google Patents. 2018.
[56]
Sugaya K, Vaidya M. Stem cell therapies for neurodegenerative diseases Exosomes, Stem Cells and MicroRNA. Springer 2018; pp. 61-84.
[http://dx.doi.org/10.1007/978-3-319-74470-4_5]
[57]
Ku J, El-Hashash A. Stem cell roles and applications in genetic neurodegenerative diseases, in stem cells for cancer and genetic disease treatment. In: Stem cells for cancer and genetic disease treatment. Springer 2018; pp. 129-47.
[58]
Ebert AD, Liang P, Wu JC. Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol 2012; 60(4): 408.
[http://dx.doi.org/10.1097/FJC.0b013e318247f642]
[59]
Takahashi K, Yamanaka S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. cell 2006; 126(4): 663-76.
[60]
Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev 2010; 24(20): 2239-63.
[http://dx.doi.org/10.1101/gad.1963910]
[61]
Baharvand H, Totonchi M, Taei A, Seifinejad A, Aghdami N, Salekdeh GH. Human-induced pluripotent stem cells: Derivation, propagation, and freezing in serum- and feeder layer-free culture conditions. Methods Mol Biol 2010; 584: 425-43.
[http://dx.doi.org/10.1007/978-1-60761-369-5_23]
[62]
Yue XS1, Fujishiro M, Nishioka C, et al. Feeder cells support the culture of induced pluripotent stem cells even after chemical fixation. PLoS One 2012; 7(3) e32707
[http://dx.doi.org/10.1371/journal.pone.0032707]
[63]
Villa-Diaz LG, Ross AM, Lahann J, Krebsbach PH. Concise review: the evolution of human pluripotent stem cell culture: from feeder cells to synthetic coatings. Stem Cells 2013; 31(1): 1-7.
[http://dx.doi.org/10.1002/stem.1260]
[64]
Centeno EG, Cimarosti H, Bithell A. 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. Mol Neurodegener 2018; 13(1): 27.
[http://dx.doi.org/10.1186/s13024-018-0258-4]
[65]
Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26(7): 795.
[http://dx.doi.org/10.1038/nbt1418]
[66]
Okano H, Nakamura M, Yoshida K, et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res 2013; 112(3): 523-33.
[http://dx.doi.org/10.1161/CIRCRESAHA.111.256149]
[67]
Yu Y, Wang X, Nyberg S. Potential and challenges of induced pluripotent stem cells in liver diseases treatment. J Clin Med 2014; 3(3): 997-1017.
[http://dx.doi.org/10.3390/jcm3030997]
[68]
Biehl JK, Russell B. Introduction to stem cell therapy. J Cardiovasc Nurs 2009; 24(2): 98-105.
[http://dx.doi.org/10.1097/JCN.0b013e318197a6a5]
[69]
Watanabe K, Ueno M, Kamiya D, et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 2007; 25(6): 681.
[http://dx.doi.org/10.1038/nbt1310]
[70]
Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 2004; 101(34): 12543-8.
[http://dx.doi.org/10.1073/pnas.0404700101]
[71]
Ladewig J, Koch P, Brustle O. Leveling Waddington: The emergence of direct programming and the loss of cell fate hierarchies. Nat Rev Mol Cell Biol 2013; 14(4): 225-36.
[http://dx.doi.org/10.1038/nrm3543]
[72]
Zhang SC, Wernig M, Duncan ID, Brüstle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001; 19(12): 1129-33.
[http://dx.doi.org/10.1038/nbt1201-1129]
[73]
Tabar V, Studer L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet 2014; 15(2): 82.
[http://dx.doi.org/10.1038/nrg3563]
[74]
Zhang N, An MC, Montoro D, Ellerby LM. Characterization of human Huntington’s disease cell model from induced pluripotent stem cells. PLoS Curr 2010; 2 RRN1193
[http://dx.doi.org/10.1371/currents.RRN1193]
[75]
Camnasio S, Delli Carri A, Lombardo A, et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington’s disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 2012; 46(1): 41-51.
[http://dx.doi.org/10.1016/j.nbd.2011.12.042]
[76]
Kondo T, Asai M, Tsukita K, et al. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell 2013; 12(4): 487-96.
[http://dx.doi.org/10.1016/j.stem.2013.01.009]
[77]
Zhang D, Pekkanen-Mattila M, Shahsavani M, Falk A, Teixeira AI, Herland A. A 3D Alzheimer’s disease culture model and the induction of P21-activated kinase mediated sensing in iPSC derived neurons. Biomaterials 2014; 35(5): 1420-8.
[http://dx.doi.org/10.1016/j.biomaterials.2013.11.028]
[78]
Cooper O, Hargus G, Deleidi M, et al. Differentiation of human ES and Parkinson’s disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci 2010; 45(3): 258-66.
[http://dx.doi.org/10.1016/j.mcn.2010.06.017]
[79]
Soldner F, Hockemeyer D, Beard C, et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136(5): 964-77.
[http://dx.doi.org/10.1016/j.cell.2009.02.013]
[80]
Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321(5893): 1218-21.
[81]
Xie C, Liu YQ, Guan YT, Zhang GX. Induced Stem Cells as a Novel Multiple Sclerosis Therapy. Curr Stem Cell Res Ther 2016; 11(4): 313-20.
[http://dx.doi.org/10.2174/1574888X10666150302110013]
[82]
Walker FO. Huntington’s disease. Lancet 2007; 369(9557): 218-28.
[http://dx.doi.org/10.1016/S0140-6736(07)60111-1]
[83]
Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington’s disease: Mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 2017; 7(7)a024240
[http://dx.doi.org/10.1101/cshperspect.a024240]
[84]
Wheeler VC, Persichetti F, McNeil SM, et al. Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet 2007; 44(11): 695-701.
[http://dx.doi.org/10.1136/jmg.2007.050930]
[85]
Lo Furno D, Mannino G, Giuffrida R. Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases. J Cell Physiol 2018; 233(5): 3982-99.
[http://dx.doi.org/10.1002/jcp.26192]
[86]
Chiu FL, Lin JT, Chuang CY, et al. Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington’s disease iPSCs. Hum Mol Genet 2015; 24(21): 6066-79.
[http://dx.doi.org/10.1093/hmg/ddv318]
[87]
Nekrasov ED, Vigont VA, Klyushnikov SA, et al. Manifestation of Huntington’s disease pathology in human induced pluripotent stem cell-derived neurons. Mol Neurodegener 2016; 11: 27.
[88]
Connor B. Concise review: the use of stem cells for understanding and treating Huntington’s disease. Stem Cells 2018; 36(2): 146-60.
[http://dx.doi.org/10.1002/stem.2747]
[89]
Bidollari E, Rotundo G, Ferrari D, et al. Generation of induced pluripotent stem cell line, CSSi004-A (2962), from a patient diagnosed with Huntington’s disease at the presymptomatic stage. Stem Cell Res (Amst) 2018; 28: 145-8.
[http://dx.doi.org/10.1016/j.scr.2018.02.014]
[90]
Bigarreau J, et al. B16 Astrocytes derived from patient specific human pluripotent stem cells: A valuable biological resource for target identification in hd?. BMJ Publishing Group Ltd. 2018.
[91]
An MC1, Zhang N, Scott G, et al. Genetic correction of Huntington’s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012; 11(2): 253-63.
[http://dx.doi.org/10.1016/j.stem.2012.04.026]
[92]
Jeon I, Lee N, Li JY, et al. Neuronal properties, in vivo effects, and pathology of a Huntington’s disease patient‐derived induced pluripotent stem cells. Stem Cells 2012; 30(9): 2054-62.
[http://dx.doi.org/10.1002/stem.1135]
[93]
Juopperi TA, Kim WR, Chiang CH, et al. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington’s disease patient cells. Mol Brain 2012; 5(1): 17.
[http://dx.doi.org/10.1186/1756-6606-5-17]
[94]
Hsiao HY, Chiu FL, Chen CM, et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington’s disease. Hum Mol Genet 2014; 23(16): 4328-44.
[http://dx.doi.org/10.1093/hmg/ddu151]
[95]
HD iPSC Consortium. Developmental alterations in Huntington’s disease neural cells and pharmacological rescue in cells and mice. Nat Neurosci 2017; 20(5): 648-60.
[http://dx.doi.org/10.1038/nn.4532]
[96]
An MC, O'Brien RN, Zhang N, et al. Polyglutamine disease modeling: epitope based screen for homologous recombination using CRISPR/Cas9 system. PLoS Curr 2014; 6 pii: ecurrents. hd.0242d2e7ad72225efa72f6964589369a
[http://dx.doi.org/10.1371/currents.hd.0242d2e7ad72225efa72f6964589369a]
[97]
Xu X, Tay Y, Sim B, et al. Reversal of phenotypic abnormalities by CRISPR/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells. Stem Cell Reports 2017; 8(3): 619-33.
[http://dx.doi.org/10.1016/j.stemcr.2017.01.022]
[98]
Tidball AM, Neely MD, Chamberlin R, et al. Genomic instability associated with p53 knockdown in the generation of Huntington’s disease human induced pluripotent stem cells. PLoS One 2016; 11(3) e0150372
[http://dx.doi.org/10.1371/journal.pone.0150372]
[99]
Khoshnam SE, Winlow W, Farbood Y, Moghaddam HF, Farzaneh M. Emerging roles of microRNAs in ischemic stroke: As possible therapeutic agents. J Stroke 2017; 19(2): 166-87.
[http://dx.doi.org/10.5853/jos.2016.01368]
[100]
Khoshnam SE, Winlow W, Farzaneh M. The Interplay of MicroRNAs in the inflammatory mechanisms following ischemic stroke. J Neuropathol Exp Neurol 2017; 76(7): 548-61.
[http://dx.doi.org/10.1093/jnen/nlx036]
[101]
Cheng P-H, Li C-L, Chang Y-F, et al. miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. Am J Hum Genet 2013; 93(2): 306-12.
[http://dx.doi.org/10.1016/j.ajhg.2013.05.025]
[102]
Reed ER, Latourelle JC, Bockholt JH, et al. MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study. Neurology 2018; 90(4): e264-72.
[http://dx.doi.org/10.1212/WNL.0000000000004844]
[103]
Fukuoka M, Takahashi M, Fujita H, et al. Supplemental treatment for Huntington’s disease with miR-132 that is deficient in Huntington’s disease brain. Mol Ther Nucleic Acids 2018; 11: 79-90.
[http://dx.doi.org/10.1016/j.omtn.2018.01.007]
[104]
Alzheimer’s A. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 2015; 11(3): 332.
[http://dx.doi.org/10.1016/j.jalz.2015.02.003]
[105]
Association AS. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement 2016; 12(4): 459-509.
[http://dx.doi.org/10.1016/j.jalz.2016.03.001]
[106]
Bloom GS, Lazo JS, Norambuena A. Reduced brain insulin signaling: a seminal process in Alzheimer’s disease pathogenesis. Neuropharmacology 2018; 136: 192-5.
[http://dx.doi.org/10.1016/j.neuropharm.2017.09.016]
[107]
Hammami S, Khadhar G. Impacts of art therapy and Alzheimer’s Disease. Middle East Journal of Age and Ageing 2018; 83(6018): 1-.
[108]
Mokhtar SH, Bakhuraysah MM, Cram DS, Petratos S. The Beta-amyloid protein of Alzheimer’s disease: communication breakdown by modifying the neuronal cytoskeleton. Int J Alzheimers Dis 2013; 2013 910502
[http://dx.doi.org/10.1155/2013/910502]
[109]
Gouras GK, Olsson TT, Hansson O. β-Amyloid peptides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics 2015; 12(1): 3-11.
[http://dx.doi.org/10.1007/s13311-014-0313-y]
[110]
Kametani F, Hasegawa M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer’s Disease. Front Neurosci 2018; 12: 25-5.
[http://dx.doi.org/10.3389/fnins.2018.00025]
[111]
Wang M, Qin L, Tang B. MicroRNAs in Alzheimer’s Disease. Front Genet 2019; 10: 153-3.
[http://dx.doi.org/10.3389/fgene.2019.00153]
[112]
Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer’s disease therapy and prevention strategies. Annu Rev Med 2017.
[http://dx.doi.org/10.1007/s12035-018-1336-x]
[113]
Li L, Chao J, Shi Y. Modeling neurological diseases using iPSC-derived neural cells. Cell Tissue Res 2018; 371(1): 143-51.
[http://dx.doi.org/10.1007/s00441-017-2713-x]
[114]
Geerts H, Dacks PA, Devanarayan V, et al. Big data to smart data in Alzheimer’s disease: The brain health modeling initiative to foster actionable knowledge. Alzheimers Dement 2016; 12(9): 1014-21.
[http://dx.doi.org/10.1016/j.jalz.2016.04.008]
[115]
Fang Y, Gao T, Zhang B, Pu J. Recent Advances: Decoding Alzheimer’s Disease with Stem Cells. Front Aging Neurosci 2018; 10: 77-7.
[http://dx.doi.org/10.3389/fnagi.2018.00077]
[116]
Majolo F, Marinowic DR, Machado DC, Da Costa JC. Important advances in Alzheimer’s disease from the use of induced pluripotent stem cells. J Biomed Sci 2019; 26(1): 15-5.
[http://dx.doi.org/10.1186/s12929-019-0501-5]
[117]
Muratore CR, Rice HC, Srikanth P, et al. The familial Alzheimer’s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Genet 2014; 23(13): 3523-36.
[http://dx.doi.org/10.1093/hmg/ddu064]
[118]
Moore S, Evans LD, Andersson T, et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep 2015; 11(5): 689-96.
[http://dx.doi.org/10.1016/j.celrep.2015.03.068]
[119]
Yagi T, Ito D, Okada Y, et al. Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum Mol Genet 2011; 20(23): 4530-9.
[http://dx.doi.org/10.1093/hmg/ddr394]
[120]
Wang C, Najm R, Xu Q, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med 2018; 24(5): 647.
[http://dx.doi.org/10.1038/s41591-018-0004-z]
[121]
Bali P, Lahiri DK, Banik A, Nehru B, Anand A. Potential for stem cells therapy in Alzheimer’s disease: Do neurotrophic factors play critical role? Curr Alzheimer Res 2017; 14(2): 208-20.
[http://dx.doi.org/10.2174/1567205013666160314145347]
[122]
Guarnieri G, Sarchielli E, Vannelli GB, Morelli A. Cell-based therapy in Alzheimer’s disease: Can human fetal cholinergic neurons “untangle the skein”? Neural Regen Res 2018; 13(12): 2105-7.
[http://dx.doi.org/10.4103/1673-5374.241459]
[123]
Raja WK, Mungenast AE, Lin YT, et al. Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer’s Disease Phenotypes. PLoS One 2016; 11(9) e0161969
[http://dx.doi.org/10.1371/journal.pone.0161969]
[124]
Arber C, Lovejoy C, Wray S. Stem cell models of Alzheimer’s disease: progress and challenges. Alzheimers Res Ther 2017; 9(1): 42-2.
[http://dx.doi.org/10.1186/s13195-017-0268-4]
[125]
Laurijssens B, Aujard F, Rahman A. Animal models of Alzheimer’s disease and drug development. Drug Discov Today Technol 2013; 10(3): e319-27.
[http://dx.doi.org/10.1016/j.ddtec.2012.04.001]
[126]
Tcw J. Human iPSC application in Alzheimer’s disease and Tau-related neurodegenerative diseases. Neurosci Lett 2019; 699: 31-40.
[http://dx.doi.org/10.1016/j.neulet.2019.01.043]
[127]
Li L, Roh JH, Chang EH, et al. iPSC modeling of presenilin1 mutation in Alzheimer’s disease with cerebellar ataxia. Exp Neurobiol 2018; 27(5): 350-64.
[http://dx.doi.org/10.5607/en.2018.27.5.350]
[128]
Chang K-H, et al. Modeling Alzheimer’s disease by induced pluripotent stem cells carrying APP D678H mutation. Mol Neurobiol 2019; 56(6): 3972-83.
[http://dx.doi.org/10.1007/s12035-018-1336-x]
[129]
Balez R, Steiner N, Engel M, et al. Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer’s disease 2016; 6, 31450: 1-16.
[http://dx.doi.org/10.1007/s12035-018-1336-x]
[130]
Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson’s disease. Subcell Biochem 2012; 65: 389-455.
[http://dx.doi.org/10.1007/978-94-007-5416-4_16]
[131]
Stoddard-Bennett T, Reijo Pera R. Treatment of Parkinson’s disease through personalized medicine and induced pluripotent stem cells. Cells 2019; 8(1): 26.
[http://dx.doi.org/10.3390/cells8010026]
[132]
Schneider SA, Obeso JA. Clinical and pathological features of Parkinson’s disease. Curr Top Behav Neurosci 2015; 22: 205-20.
[http://dx.doi.org/10.1007/7854_2014_317]
[133]
Postuma RB, Berg D, Adler CH, et al. The new definition and diagnostic criteria of Parkinson’s disease. Lancet Neurol 2016; 15(6): 546-8.
[http://dx.doi.org/10.1016/S1474-4422(16)00116-2]
[134]
Lee DJ, Dallapiazza RF, De Vloo P, Lozano AM. Current surgical treatments for Parkinson’s disease and potential therapeutic targets. Neural Regen Res 2018; 13(8): 1342-5.
[http://dx.doi.org/10.4103/1673-5374.235220]
[135]
Stoker TB, Torsney KM, Barker RA. Emerging treatment approaches for Parkinson’s Disease. Front Neurosci 2018; 12: 693-3.
[http://dx.doi.org/10.3389/fnins.2018.00693]
[136]
Carroll CB, Wyse RKH. Simvastatin as a potential disease-modifying therapy for patients with Parkinson’s disease: Rationale for clinical trial, and current progress. J Parkinsons Dis 2017; 7(4): 545-68.
[http://dx.doi.org/10.3233/JPD-171203]
[137]
Kriks S1, Shim JW, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 2011; 480(7378): 547-51.
[http://dx.doi.org/10.1038/nature10648]
[138]
Marton RM, Ioannidis JP. A Comprehensive analysis of protocols for deriving dopaminergic neurons from human pluripotent stem cells. Stem Cells Transl Med 2019; 8(4): 366-74.
[http://dx.doi.org/10.1002/sctm.18-0088]
[139]
Gonzalez R, Garitaonandia I, Semechkin R. Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells Google Patents. 2018.
[140]
Dettmer U, Newman AJ, Soldner F, et al. Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun 2015; 6: 7314.
[http://dx.doi.org/10.1038/ncomms8314]
[141]
Ryan SD, Dolatabadi N, Chan SF, et al. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. Cell 2013; 155(6): 1351-64.
[http://dx.doi.org/10.1016/j.cell.2013.11.009]
[142]
Chung CY, Khurana V, Auluck PK, et al. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science 2013; 342(6161): 983-7.
[http://dx.doi.org/10.1126/science.1245296]
[143]
Devine MJ, Ryten M, Vodicka P, et al. Parkinson’s disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun 2011; 2: 440.
[http://dx.doi.org/10.1038/ncomms1453]
[144]
Byers B, Lee HL, Reijo Pera R. Modeling Parkinson’s disease using induced pluripotent stem cells. Curr Neurol Neurosci Rep 2012; 12(3): 237-42.
[http://dx.doi.org/10.1007/s11910-012-0270-y]
[145]
Bose A, Beal MF. Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson’s disease. Eur J Neurosci 2019; 49(4): 525-32.
[http://dx.doi.org/10.1111/ejn.14264]
[146]
Baden P, Yu C, Deleidi M. Insights into GBA Parkinson’s disease pathology and therapy with induced pluripotent stem cell model systems. Neurobiol Dis 2019.
[http://dx.doi.org/10.1016/j.nbd.2019.01.023]
[147]
Shaltouki A, Sivapatham R, Pei Y, et al. Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Reports 2015; 4(5): 847-59.
[http://dx.doi.org/10.1016/j.stemcr.2015.02.019]
[148]
Cooper O, Seo H, Andrabi S, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Transl Med 2012; 4(141) 141ra90
[http://dx.doi.org/10.1126/scitranslmed.3003985]
[149]
Liu GH, Qu J, Suzuki K, et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012; 491(7425): 603.
[http://dx.doi.org/10.1038/nature11557]
[150]
Nguyen HN, Byers B, Cord B, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011; 8(3): 267-80.
[http://dx.doi.org/10.1016/j.stem.2011.01.013]
[151]
Cavalleri L, Merlo Pich E, Millan MJ, et al. Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling. Mol Psychiatry 2018; 23(4): 812.
[http://dx.doi.org/10.1038/mp.2017.241]
[152]
Chung SY, Kishinevsky S, Mazzulli JR, et al. Parkin and PINK1 patient iPSC-derived midbrain dopamine neurons exhibit mitochondrial dysfunction and α-synuclein accumulation. Stem Cell Reports 2016; 7(4): 664-77.
[http://dx.doi.org/10.1016/j.stemcr.2016.08.012]
[153]
Cobb MM, Ravisankar A, Skibinski G, Finkbeiner S. iPS cells in the study of PD molecular pathogenesis. Cell Tissue Res 2018; 373(1): 61-77.
[http://dx.doi.org/10.1007/s00441-017-2749-y]
[154]
Zhu L, Sun C, Ren J, et al. Stress-induced precocious aging in PD-patient iPSC-derived NSCs may underlie the pathophysiology of Parkinson’s disease. Cell Death Dis 2019; 10(2): 105.
[http://dx.doi.org/10.1038/s41419-019-1313-y]
[155]
Volonte D, Zou H, Bartholomew JN, Liu Z, Morel PA, Galbiati F. Oxidative stress-induced inhibition of Sirt1 by caveolin-1 promotes p53-dependent premature senescence and stimulates the secretion of interleukin 6 (IL-6). J Biol Chem 2015; 290(7): 4202-14.
[http://dx.doi.org/10.1074/jbc.M114.598268]
[156]
Hofmann KW, Schuh AF, Saute J, et al. Interleukin-6 serum levels in patients with Parkinson’s disease. Neurochem Res 2009; 34(8): 1401-4.
[http://dx.doi.org/10.1007/s11064-009-9921-z]
[157]
Li H, Jiang H, Zhang B, Feng J. Modeling Parkinson’s Disease Using Patient-specific Induced Pluripotent Stem Cells. J Parkinsons Dis 2018; 8(4): 479-93.
[http://dx.doi.org/10.3233/JPD-181353]
[158]
Devine MJ, Ryten M, Vodicka P, et al. Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun 2011; 2: 440.
[http://dx.doi.org/10.1038/ncomms1453]
[159]
Byers B, Cord B, Nguyen HN, et al. SNCA triplication Parkinson’s patient’s iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One 2011; 6(11) e26159
[http://dx.doi.org/10.1371/journal.pone.0026159]
[160]
Oliveira LM, Falomir-Lockhart LJ, Botelho MG, et al. Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson’s patient-derived induced pluripotent stem cells. Cell Death Dis 2015; 6(11) e1994
[http://dx.doi.org/10.1038/cddis.2015.318]
[161]
Grossman M. Amyotrophic lateral sclerosis—a multisystem neurodegenerative disorder. Nat Rev Neurol 2019; 15(1): 5.
[http://dx.doi.org/10.1038/s41582-018-0103-y]
[162]
Ajroud-Driss S, Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochimica Et Biophysica Acta (BBA)-. Molecular Basis of Disease 2015; 1852(4): 679-84.
[http://dx.doi.org/10.1016/j.bbadis.2014.08.010]
[163]
Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017; 377(2): 162-72.
[http://dx.doi.org/10.1056/NEJMra1603471]
[164]
Fujimori K, Ishikawa M, Otomo A, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med 2018; 24(10): 1579.
[http://dx.doi.org/10.1038/s41591-018-0140-5]
[165]
Afroz T, Pérez-Berlanga M, Polymenidou M. Structural Transition, Function and Dysfunction of TDP-43 in Neurodegenerative Diseases. Chimia (Aarau) 2019; 73(6): 380-90.
[http://dx.doi.org/10.2533/chimia.2019.380]
[166]
Sun X, Song J, Huang H, Chen H, Qian K. Modeling hallmark pathology using motor neurons derived from the family and sporadic amyotrophic lateral sclerosis patient-specific iPS cells 2018; 9(1): 315.
[http://dx.doi.org/10.1186/s13287-018-1048-1]
[167]
Martin S, Al Khleifat A, Al-Chalabi A. What causes amyotrophic lateral sclerosis? F1000 Res 2017; 6: 371-1.
[http://dx.doi.org/10.12688/f1000research.10476.1]
[168]
Hedges EC, Mehler VJ, Nishimura AL. The use of stem cells to model amyotrophic lateral sclerosis and frontotemporal dementia: From basic research to regenerative medicine. Stem Cells Int 2016; 2016: 9279516-6.
[http://dx.doi.org/10.1155/2016/9279516]
[169]
Lee S, Huang EJ, Modeling ALS. Brain Res 2017; 1656: 88-97.
[http://dx.doi.org/10.1016/j.brainres.2015.10.003]
[170]
Guo W, Fumagalli L, Prior R, Van Den Bosch L, et al. Current advances and limitations in modeling ALS/FTD in a dish using induced pluripotent stem cells. Front Neurosci 2017; 11: 671.
[http://dx.doi.org/10.3389/fnins.2017.00671]
[171]
Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are We Any Closer to Registering a New Treatment? Front Aging Neurosci 2017; 9: 68-8.
[http://dx.doi.org/10.3389/fnagi.2017.00068]
[172]
Egawa N, Inoue H. ALS disease modeling and drug screening using patient-specific iPS cells. Rinsho Shinkeigaku 2013; 53(11): 1020-2.
[173]
de Boer AS, Eggan K. A perspective on stem cell modeling of amyotrophic lateral sclerosis. Cell Cycle 2015; 14(23): 3679-88.
[http://dx.doi.org/10.1080/15384101.2015.1093712]
[174]
Halevy T, Urbach A. Comparing ESC and iPSC—based models for human genetic disorders. J Clin Med 2014; 3(4): 1146-62.
[http://dx.doi.org/10.3390/jcm3041146]
[175]
Berry BJ, Smith AST, Young JE, Mack DL. Advances and current challenges associated with the use of human induced pluripotent stem cells in modeling neurodegenerative disease. Cells Tissues Organs 2018; 205(5-6): 331-49.
[http://dx.doi.org/10.1159/000493018]
[176]
Bordoni M, Rey F, Fantini V, et al. From neuronal differentiation of iPSCs to 3D neural organoids: Modeling of neurodegenerative diseases. Neurodegeneration. Int J Mol Sci 2018; 19(12) pii: E3972
[177]
Papp B, Plath K. Epigenetics of reprogramming to induced pluripotency. Cell 2013; 152(6): 1324-43.
[http://dx.doi.org/10.1016/j.cell.2013.02.043]
[178]
Hochedlinger K, Jaenisch R. Induced pluripotency and epigenetic reprogramming. Cold Spring Harb Perspect Biol 2015; 7(12) pii: a019448
[http://dx.doi.org/10.1101/cshperspect.a019448]
[179]
Liang G, Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell 2013; 13(2): 149-59.
[http://dx.doi.org/10.1016/j.stem.2013.07.001]

Rights & Permissions Print Cite
Article Metrics
80
13
© 2024 Bentham Science Publishers | Privacy Policy